Which medications have a narrow therapeutic range and require therapeutic drug monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications with Narrow Therapeutic Range Requiring Therapeutic Drug Monitoring

Multiple drug classes have narrow therapeutic ranges and require therapeutic drug monitoring (TDM), with the most critical being aminoglycosides, vancomycin, lithium, digoxin, certain antiepileptics (phenytoin, carbamazepine), immunosuppressants (cyclosporine, tacrolimus, sirolimus), and select tyrosine kinase inhibitors.

Core Principles of Narrow Therapeutic Index Drugs

Narrow therapeutic index (NTI) drugs are defined as medications where small differences in dose or blood concentration may lead to serious therapeutic failures or life-threatening adverse reactions 1. The FDA has identified 33 drug products with 14 distinct active ingredients as NTI drugs requiring special monitoring 1.

Antimicrobials Requiring TDM

Aminoglycosides

  • Dosing strategy: Once-daily dosing (5-7 mg/kg gentamicin equivalent) optimizes peak concentrations while minimizing renal toxicity 2
  • Monitoring rationale: Peak drug plasma concentrations correlate directly with clinical success for gram-negative bacteremia and nosocomial pneumonia 2
  • Target: Trough concentrations must be sufficiently low to minimize nephrotoxicity 2
  • Critical in: Patients with preserved renal function; those with chronic mild renal impairment require extended intervals (up to 3 days) between doses 2

Vancomycin

  • Loading dose: 25-30 mg/kg based on actual body weight for sepsis/septic shock 2
  • Target trough: 15-20 mg/L to maximize pharmacodynamic targets and optimize clinical outcomes 2
  • Monitoring timing: Pre-dose trough concentrations 2
  • Rationale: Inadequate early trough concentrations (relative to pathogen MIC) associate with clinical failure in serious MRSA infections, including nosocomial pneumonia and septic shock 2

Beta-lactams (in critically ill patients)

  • Extended or continuous infusion with TDM should be considered in critically ill patients with obesity to increase likelihood of therapeutic concentrations 3
  • Target: 100% time above MIC (T>MIC) for severe infections including sepsis 2

Colistin and Other Antibiotics in Renal Replacement Therapy

TDM is recommended for aminoglycosides, beta-lactams, glycopeptides, linezolid, and colistin in patients receiving intermittent or continuous renal replacement therapy due to highly variable drug exposure 4

Immunosuppressants

Cyclosporine

  • Monitoring method: Drug levels 2 hours post-dosing are more sensitive predictors of outcome than trough monitoring 5
  • Rationale: Narrow therapeutic window, drug-induced nephrotoxicity, and significant inter/intra-patient variability 6

Tacrolimus

  • Target range: 5-10 μg/L in whole blood (varies by organ and time post-transplant) 6
  • Clinical correlation: Low concentrations associate with rejection; high concentrations with nephrotoxicity 6
  • Monitoring: Trough (pre-dose) whole blood concentrations 6

Sirolimus

  • Suggested range: 5-10 μg/L in whole blood 6
  • Note: Consensus guidelines indicate insufficient information for firm recommendations, but monitoring is practiced 6

Mycophenolic Acid

  • Indications for TDM: Relationship between pharmacokinetic parameters and clinical outcomes, inter-patient variability despite fixed doses, drug-drug interactions, and influence of kidney function 6

Antiepileptics

Phenytoin and Carbamazepine

  • Strong indication: Both have narrow therapeutic indices where therapeutic monitoring is indicated 7
  • Clinical necessity: Consequences of undertreatment (seizures) cannot be recognized clinically until serious events occur 7

Cardiovascular Medications

Lithium

  • Mandatory monitoring: Required for safety reasons 8
  • Classification: Level 1 (strongly recommended) for TDM 8

Digoxin

  • Indication: Narrow therapeutic index with established therapeutic range 7
  • Monitoring necessity: Prevents toxicity while maintaining efficacy

Antidepressants (Select Agents)

Certain antidepressants warrant TDM based on established therapeutic ranges and evidence of concentration-dependent efficacy 8:

  • Level 1 (strongly recommended): Drugs with controlled trials showing TDM benefit
  • Level 2 (recommended): Agents with suggested ranges from fixed-dose studies showing intoxication at supratherapeutic levels

Tyrosine Kinase Inhibitors

Several TKIs meet criteria for TDM 9:

  • Established targets: Crizotinib, erlotinib, gefitinib, imatinib, nilotinib, pazopanib, sunitinib (for efficacy)
  • Safety targets: Dasatinib, sunitinib
  • Rationale: Long-term therapy, significant inter-individual variability, narrow therapeutic index, well-defined exposure-response relationships 9

Biologic Drugs

TNF Inhibitors (Infliximab, Adalimumab)

  • Proactive TDM: Suggested for adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis receiving intravenous infliximab maintenance therapy 10
  • Benefit: 14% absolute increase in sustained disease remission/control compared to standard care 10
  • Reactive TDM: Recommended when patients have active disease with objective inflammation 11

Anti-Tuberculosis Medications

Isoniazid

  • High-dose monitoring: 15-20 mg/kg daily requires monitoring 12
  • Rationale: Narrow therapeutic index and significant inter-individual variability 13
  • Strategy: Limited sampling strategies can reduce patient burden while maintaining accuracy 13

Special Populations Requiring Enhanced Monitoring

Critically Ill Patients

Physiologic perturbations dramatically alter pharmacokinetics 2:

  • Unstable hemodynamics and increased cardiac output
  • Increased extracellular volume (markedly increasing volume of distribution)
  • Variable kidney/hepatic perfusion affecting clearance
  • Augmented renal clearance in early sepsis leading to decreased drug levels 2

Patients with Chronic Kidney Disease

Monitor eGFR, electrolytes, and therapeutic medication levels for drugs with narrow therapeutic windows, potential adverse effects, or nephrotoxicity 14. Use equations combining creatinine and cystatin C, or measured GFR when more accuracy is required for drug-related decision-making 14.

Patients with Obesity

Consider eGFR non-indexed for body surface area, especially for medications with narrow therapeutic range or requiring minimum concentration for effectiveness 14

Common Pitfalls to Avoid

  1. Timing errors: Always collect samples at steady state and at trough (pre-dose) unless otherwise specified
  2. Ignoring loading doses: Drugs with low volumes of distribution (vancomycin, colistin, teicoplanin) require loading doses in critically ill patients due to expanded extracellular volume 2
  3. Failure to restart medications: After planned discontinuation during acute illness or surgery, ensure clear communication about when to restart 14
  4. Under-dosing in early treatment: Particularly common in critically ill septic patients despite TDM availability 2
  5. Assuming standard dosing suffices: In critically ill patients, standard dosing frequently results in subtherapeutic levels 2

References

Research

Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations.

Clinical pharmacology and therapeutics, 2025

Research

A review on therapeutic drug monitoring of immunosuppressant drugs.

Iranian journal of basic medical sciences, 2011

Research

'Just a repeat' - When drug monitoring is indicated.

Australian family physician, 2013

Guideline

treatment of drug-resistant tuberculosis. an official ats/cdc/ers/idsa clinical practice guideline.

American Journal of Respiratory and Critical Care Medicine, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.